NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Centre for Health Technology Evaluation

# Technology Appraisal Committee A meeting minutes

**Minutes:** Confirmed

**Date:** Wednesday 3 May 2023

**Location:** Via Zoom

## Attendees

Committee members present

1. Dr James Fotheringham (Chair) Present for all items
2. Dr Peter Baker-Gulliver Present for all items
3. Richard Ballerand Present for all items
4. Dr Patrick De Barr (Observer) Present for all items
5. Dr Steve Edwards Present for all items
6. Mohamad Farhat Present for all items
7. Dr Fiona MacPherson Smith Present for all items
8. Dr Pratheeban Nambyiah Present for all items
9. Hugo Pedder Present for all items
10. Becky Pennington Present for all items
11. Dominic Pivonka Present for all items
12. Dr Mohit Sharma Items 1 to 4.1.3
13. Alan Thomas Present for all items
14. Jaqueline Tomlinson Present for all items

NICE staff (key players) present

Janet Robertson, Associate Director Present for all items

Thomas Feist, Project Manager Present for all items

Joanna Richardson, Heath Technology Assessment Adviser Present for all items

Alexandra Sampson, Heath Technology Assessment Analyst Present for all items

Jacoline Bouvy, Programme Director Present for all items

Helen Barnett, Content Designer – Guidance Present for all items

Ella Fitzpatrick, Public Involvement Adviser, PIP Items 1 to 4.1.3

Lyn Davies, Coordinator, Corporate Office Items 1 to 4.1.3

Rosalee Mason, Coordinator, Corporate Office Items 1 to 4.1.3

Adam Storrow, Resource Impact Lead, RIA Present for all items

Carl Jackson, Assistant Project Manager, COT Present for all items

Marcia Miller, Administrator, TA Present for all items

NICE staff (observers) present

Emilene Coventry, Heath Technology Assessment Analyst Items 1 to 4.1.3

Jess Crooks, Apprentice, CCT Items 4 to 4.1.3

External assessment group representatives present

Robert Hodgson, NHS Centre for Reviews and Dissemination and Centre for Health Economics - York Items 1 to 4.2.1

Ros Wade, NHS Centre for Reviews and Dissemination and Centre for Health Economics - York Items 1 to 4.2.1

Clinical, Patient & NHS England experts present

Jordi Diaz-Manera, Consultant Neurologist, Clinical Expert nominated by Muscular Dystrophy UK, Items 1 to 4.1.3

Jane Randall, Patient Expert, nominated by AGSD and MDUK, Items 1 to 4.1.3

Jeffrey Harvey, Patient Expert, nominated by Pompe Support Network, Items 1 to 4.1.3

Ayesha Ali, Medical Adviser Highly Specialised Service, NHSE Commissioning Expert Present for all items

## Minutes

### Introduction to the meeting

* 1. The chair welcomed members of the committee and other attendees present to the meeting.
	2. The chair noted apologies from Ana Duarte, Andrew Champion, Dr David Maudgil, Prof. G.J. Melendez-Torres, Dr Justin Daniels, Min Ven Teo, Dr Radha Todd.

### News and announcements

* 1. The chair welcomed Dr Patrick De Barr who has joined the committee as a Pharmaceutical Physician. The chair stated that he is attending this meeting as an observer and does not count towards quoracy.
	2. The chair stated that Louis Choo has resigned from the committee with immediate effect.

### Minutes from the last meeting

* 1. The committee approved the minutes of the committee meeting held on Tuesday 4 April 2023.

### Appraisal of Cipaglucosidase alfa with miglustat for treating late-onset Pompe disease [ID3771]

* 1. Part 1 – Open session
		1. The chair welcomed the invited experts, external assessment group representatives, members of the public and company representatives from Amicus Therapeutics.
		2. The chair asked all committee members and experts, external assessment group representatives and NICE staff present to declare any relevant interests in relation to the item being considered.
* Dominic Pivonka declared an indirect financial interest as he has a friend who is Regional Medical Lead for Pompe disease at Amicus Therapeutics. It was agreed that his declaration would not prevent Dominic Pivonka from participating in discussions on this appraisal.
* Jordi Diaz-Manera declared professional and direct financial interests as he has received funding from several companies associated with Amicus Therapeutics and participated on advisory boards It was agreed that his declaration would not prevent Jordi Diaz-Manera from providing expert advice to the committee.
* No further interests were declared for this appraisal.
	+ 1. The Chair led a discussion of the evidence presented to the committee. This information was presented to the committee by Dr Pratheeban Nambyiah (Clinical), Dr Steve Edwards (Cost), Richard Ballerand (Lay).
	1. Part 2a – Closed session (clinical and patient experts, company representatives and members of the public were asked to leave the meeting).
		1. The committee discussed confidential information submitted for this item.
	2. Part 2b – Closed session (external assessment group representatives were asked to leave the meeting)
		1. The committee then agreed on the content of the Draft Guidance (DG) or Final Draft Guidance (FDG). The committee decision was reached.
		2. The committee asked the NICE technical team to prepare the Draft Guidance (DG) or Final Draft Guidance (FDG) in line with their decisions.
* Further updates will be available on the topic webpage in due course: <https://www.nice.org.uk/guidance/indevelopment/gid-ta10887>.

### Date of the next meeting

The next meeting of the Technology Appraisal Committee A will be held on Tuesday 6 June 2023 and will start promptly at 9.30am.